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ABSTRACT
Comparative modeling of the DNA-binding domain
of human HSF1 facilitated the prediction of possi-
ble binding pockets for small molecules and defi-
nition of corresponding pharmacophores. In silico
screening of a large library of lead-like compounds
identified a set of compounds that satisfied the
pharmacophoric criteria, a selection of which com-
pounds was purchased to populate a biased sub-
library. A discriminating cell-based screening as-
say identified compound 001, which was subjected
to systematic analysis of structure–activity relation-
ships, resulting in the development of compound 115
(IHSF115). IHSF115 bound to an isolated HSF1 DNA-
binding domain fragment. The compound did not af-
fect heat-induced oligomerization, nuclear localiza-
tion and specific DNA binding but inhibited the tran-
scriptional activity of human HSF1, interfering with
the assembly of ATF1-containing transcription com-
plexes. IHSF115 was employed to probe the human
heat shock response at the transcriptome level. In
contrast to earlier studies of differential regulation
in HSF1-naı¨ve and -depleted cells, our results sug-
gest that a large majority of heat-induced genes is
positively regulated by HSF1. That IHSF115 effectively
countermanded repression in a significant fraction
of heat-repressed genes suggests that repression
of these genes is mediated by transcriptionally ac-
tive HSF1. IHSF115 is cytotoxic for a variety of human
cancer cell lines, multiple myeloma lines consistently
exhibiting high sensitivity.
INTRODUCTION
The stress or heat shock response (HSR) is a key mecha-
nism for maintaining cellular proteostasis under conditions
of heat or other proteotoxic stress. The response encom-
passes increased expression of so called heat shock proteins
(HSPs), molecular chaperones that reduce aggregation of
misfolded proteins and promote their refolding or disposal
(1,2). Activation of the HSR is triggered by protein damage
that occurs in cells exposed to excessive but non-lethal heat
or to chemicals or other conditions that cause proteins to
become denatured (3,4).
The master regulator of the mammalian HSR is heat
shock transcription factor 1 (HSF1) (5,6). In the absence of
a stress, HSF1 is predominantly present in cells in an inac-
tive, hetero–oligomeric complex comprising HSP90 and co-
chaperones (7–10). Several additional proteins are known
or inferred to bind HSF1 or HSF1 complex, including
CHIP (11), HDAC6 (12,13), p97/VCP (12,13), DAXX (14),
14-3-3 (15), FILIP-1L (16) and HSBP1 (17). More recently,
this list was expanded considerably by Fujimoto et al. and,
most notably, now includes ATF1 and RPA1, which pro-
teins interact with the HSF1DNA-binding domain (18,19).
Stress-mediated activation of HSF1 and maintenance
of the factor in an active form involves a multitude of
events. An early event is the dissociation of HSP90 or
HSP90 complex from the inactive HSF1 complex and the
consequential homo-trimerization of HSF1 (7,20). HSF1
trimers are capable of specific DNA-binding. However,
whether they are also transactivation-competent appears
to depend in part on whether they are capable of escap-
ing re-associationwithHSP90 and/orHSP70 (21,22). Tran-
scriptional activity of HSF1 will also depend on DAXX
as well as on its phosphorylation status (14,23–25). Re-
cruitment of HSF1 to target promoters in response to
a stress is mediated by ATF1/CREB (19). ATF1/CREB
regulates the stress-induced HSF1 transcription complex
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that includes BRG1 chromatin-remodeling complex and
p300/CBP. The former complex promotes an active chro-
matin state in the promoters, whereas p300/CBP acceler-
ates the shutdown of HSF1 DNA-binding activity as well
as stabilizes HSF1 against proteasomal degradation during
recovery from stress (19,26). This shutdown is counteracted
by SIRT1-mediated deacetylation (27).
Beyond regulation of typical HSR genes such as HSP
genes, activated HSF1 influences the activities of genes re-
lated to a variety of basic cellular processes. This HSF1-
induced program may facilitate oncogenic transformation
and maintenance of a malignant phenotype (28–33). Dai et
al. demonstrated that genetic elimination of HSF1 protects
mice from tumors induced by mutations in the RAS onco-
gene or a hot spot mutation in tumor suppressor gene P53
and that ablation of HSF1 byRNA interference is cytotoxic
to various cancer cell lines (31). Work by others in differ-
ent in vitro and in vivo cancer models permitted generaliza-
tion of these findings (34–37). Consistent with the depen-
dence of many cancers on HSF1 activity is the observation
of elevated nuclear levels of HSF1 in a high proportion of
breast cancer samples from in situ and invasive breast car-
cinomas obtained from 1841 study participants (38). High
levels of HSF1 were correlated with poor survival. A subse-
quent study found high levels of nuclear HSF1 to be com-
mon in a wide range of cancers (30). These findings pro-
pound HSF1 as a promising new cancer therapeutic target.
A specific inhibitor that directly targets HSF1 could be
expected to be a useful tool for better understanding mech-
anisms of regulation of HSF1 activity as well as for inves-
tigating the consequences of acute interruption of HSF1
function. Furthermore, such an inhibitor may be devel-
oped into a therapeutic agent that may prove valuable in
the therapy of multiple cancer types and other conditions
dependent on HSF1 activity. To date, no such specific in-
hibitor has been developed. An inhibitory nitropyridine
compound named KRIBB11 has been described that may
interact with HSF1 or a complex comprising HSF1 (39).
However, the molecule lacks specificity, belonging to a class
of compounds that are effective inhibitors of reverse tran-
scriptases (40). It is noted that an RNA aptamer has been
reported that is capable of inhibiting HSF1 binding to its
target genes in transfected human cells (41). Herein we re-
port on the de novo development of a drug-like inhibitor that
targets human HSF1 and describe its mechanism of inhibi-
tion as well as biological consequences of exposure to this
inhibitor.
MATERIALS AND METHODS
Chemical compounds
Details of syntheses are provided under Supplemental
Methods, Supporting Information. All compounds were
characterized by liquid chromatography mass spectrometry
(LCMS) and 1H nuclearmagnetic resonance (NMR). Com-
pounds 001 and 004 were obtained from AKos Consulting
& Solutions GmbH and Ambinter, respectively.
Plasmids and subcloning
A fragment containing Renilla luciferase (RLUC) coding
sequences and SV40 polyA sequences was polymerase chain
reaction (PCR)-amplified from phRL-CMV (Promega)
using primers 5′-TCACTATAAGCTTGCCACCATGG-3′
and 5′-CCTGGAAGCTTATCGATTTTACCA-3′, di-
gested with HindIII and inserted into the HindIII site of
pSP72-Hsp70B (42). The resulting construct was designated
pHsp70B-Ren. A firefly luciferase (FLUC) gene flanked by
a LEXA binding site-containing promoter and SV40 polyA
sequences was PCR-amplified from pLexA-Luc (21) using
primers 5′-ATCTTATGGTACCGTAACTGAGC-3′ and
5′-CAAGGGTACCGGTCGACGGAT-3′, digested with
KpnI and inserted into the KpnI site of pHsp70B-Ren. Re-
sulting construct pHsp70B-Ren/LexA-Luc contained the
latter HSP70B-RLUC and LEXA-FLUC genes arranged
in the same orientation. pLexAHSF1wt is a pcDNA3.1(+)-
derived plasmid (Invitrogen) that encodes a chimeric HSF1
containing the first 87 codons of LEXA linked in frame
to codon 79 of human HSF1 (43,44). In the version used
herein, HSF1 amino acids 183–203 were replaced by
KQLLQQILNLIVNILNQSKLI. To prepare pGSLink-
HSF1WT, an internal NcoI site in the HSF1-coding
sequence was destroyed by QuickChange site-directed
mutagenesis of pcDNA3.1(+)-derived pHSF1WT, using
primers 5′-CCTGCCAGCCCAATGGCCTCCCC-3′ and
5′-GGGGAGGCCATTGGGCTGGCAGG-3′. The result-
ing construct served as template for PCR amplification us-
ing primers 5′-GCTTGTTAACCATGGATCTGC-3′ and
5′-TGTCCCGGGAGACAGTGGGGTCCTTGGCTTT-
3′. The PCR product was digested with NcoI and
XmaI and inserted into the NcoI/XmaI sites of
pGSLink (45). To prepare pGSLink-HSF1DBD, the
HSF1 DNA-binding domain-encoding sequence of
HSF1 was PCR-amplified from pHSF1WT using
primers 5′-GCTTGTTAACCATGGATCTGC-3′ and
5′-TGTCCCGGGATCTTTATGTC-3′. The PCR product
was digested with NcoI and XmaI and inserted into
the NcoI/XmaI sites of pGSLink. To obtain pCTF-
HSF1WT, a plasmid encoding a FLAG peptide fused
to the C-terminus of HSF1, the HSF1-coding sequence
was PCR-amplified from pHSF1WT using primers
5′-GTTAGGTACCATGGATCTGCCCGTGG-3′ and
5′-GTTAGGTACCGGAGACAGTGGGGTCCTTG-3′.
The PCR product was digested with KpnI and inserted
into the KpnI site of pCMV-(DYKDDDDK)-C (Clontech).
All subcloning and mutagenesis steps were monitored by
restriction analysis and nucleotide sequencing.
Cell culture, transfection and isolation of cell lines
Human HeLa (ATCC CCL-2), Saos-2 (ATCC HTB-85),
MG-63 (ATCC CRL-1427), U-2 OS (ATCC HTB-96),
HepG2 (ATCC HB-8065), T-47D (ATCC HTB-133), BT-
474 (ATCC HTB20), A549 (ATCC CCL185), MDA-MB-
453 (ATCC HTB131), sNF02.2 (ATCC CRL-2885) and
sNF96.2 (ATCC CRL-2884) cells were cultured in Dul-
becco’smodifiedEagle’smedium (DMEM;Lonza).Human
THP-1 (ATCC TIB202), NCI-H3122, NCI-H2228 (ATCC
CRL-5935), NCI-H1975 (ATCC CRL-5908), NCI-H460
Nucleic Acids Research, 2017 3
(ATCC HTB177), HCC1143 (ATCC CRL-2321), MDA-
MB-231 (ATCCHTB26), IM-9 (ATCCCCL159),MNNG-
HOS (ATCCCRL1547), A673 (ATCCCRL1598), U266B1
(ATCC TIB-196), RPMI 8266 (ATCC CCL-155), MM.1R
(ATCC CRL-2975) and MM.1S (ATCC CRL2974) cells
were cultured in RPMI-1640 medium (Lonza). Human
BT-20 cells (ATCC HTB19), CAMA-1 cells (ATCC HTB-
21) and normal human embryonic WI-38 fibroblasts
(ATCC CCL-75) were cultured in Eagle’s minimum es-
sential medium (EMEM; Lonza). Human MCF-7 cells
(ATCC HTB-22) were cultured in EMEM supplemented
with 1% non-essential amino acids. Human SK-N-SH cells
(ATCC HTB11) were cultured in DMEM supplemented
with 1.25 mM HEPES, pH 7.3. Human SK-OV-3 (ATCC
HTB77), OV56 (ECACC 96020759) and PEA1 (ECACC
10032306) cells were cultured in RPMI-1640 supplemented
with 1 mM sodium pyruvate. Human PC-3 cells (ATCC
CRL-1435) were cultured in F-12 Coon’s modified medium
(Lonza). DMEM, EMEM and RPMI media were supple-
mented with 10% (v/v) fetal bovine serum. F-12 Coon’s
modified medium was supplemented with 7% (v/v) fetal
bovine serum. All media were supplemented with 10 U/ml
penicillin and 0.01 mg/ml streptomycin. Cells were main-
tained in a humidified 5% CO2 atmosphere at 37◦C. Ex-
cept for NCI-H3122 which was from NCI, and OV56 and
PEA1 which were from ECACC, all the above-mentioned
cell lines were from ATCC. To obtain cell line Z74 con-
taining HSP70B-RLUC, LEXA-FLUC and CMV-LEXA-
HSF1 genes, HeLa cells were co-transfected with pHsp70B-
Ren/LexA-Luc and pLexAHSF1 (5:1 molar ratio). To ob-
tain cell line CTF135 harboring a FLAG-tagged version of
the CMV-HSF1 gene, HeLa cells were co-transfected with
pCTF-HSF1WT and a pcDNA3.1-derived vector expressing
a neomycin resistance gene (42) (4:1 molar ratio). Cell lines
were isolated after selection with 600 g/ml G418. HSF2-
deficient cell line HF73 was prepared by transfection of
HeLa cells with equal amounts of the three plasmids of the
human HSF2 sgRNA CRISPR/Cas9 All-in-One Lentivec-
tor set ofApplied BiologicalMaterials. Cell lines we isolated
after selection with 1.3 g/ml puromycin. All transfections
employed Lipofectamine reagent (Invitrogen).
Measurement of reporter gene activities in Z74 cells
Z74 cells (1 × 104) were seeded in 96-well plates and cul-
tured for 24 h. At that time, cultures were pre-incubated for
2 h with a compound to be tested or vehicle, heated, typ-
ically at 43◦C, for 30 min in a thermostatically controlled
water bath and then incubated for an additional 6 h at
37◦C. FLUC and RLUC activities were determined using
the Dual-Glo™ Luciferase Assay System (Promega). Lu-
ciferase light counts were detected in a Wallac Microbeta
Trilux-1450 Luminometer (Perkin–Elmer).
Protein purification and surface plasmon resonance (SPR)
analysis
Escherichia coli BL21(DE3) Codon Plus cells
(Stratagene/Agilent Technologies) were transformed with
pGSLink-HSF1WT or pGSLink-HSF1DBD. Expression
of His-tagged proteins induced by 0.1 mM isopropyl-1-
thio--D-galactopyranoside was for 2.5 h (HSF1WT) or 5
h (HSF1DBD) at 20◦C. Cells were harvested by centrifu-
gation, re-suspended in lysis buffer (20 mM Tris–HCl, pH
7.9, 300 mMNaCl) supplemented with a protease inhibitor
cocktail (Complete, Roche Applied Science) and disrupted
on ice using a sonicator. Soluble fractions were purified on
5-ml HisTrap FF columns in an A¨KTA Prime Plus FPLC
system (both from GE Healthcare Life Sciences) at a flow
rate of 1 ml/min. Columns were pre-equilibrated with lysis
buffer. Following washes with lysis buffer containing 4 mM
imidazole, proteins were eluted with lysis buffer containing
400 mM imidazole. Purified HSF1WTwas dialyzed against
lysis buffer. The proteins were concentrated to 10 mg/ml
using concentrator devices (Vivaspin, GE Healthcare
Life Sciences) with a 10 kDa (HSF1WT) or a 3 kDa
(HSF1DBD) cut-off, respectively. Purity of the proteins
was determined by Coomassie blue staining of sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels. Surface plasmon resonance (SPR) assays were
performed using a Biacore 3000 instrument (Biacore AB).
HSF1WT and HSF1DBD proteins were immobilized on
CM5 sensor chips (Biacore) using a standard amine cou-
pling procedure, after activation of surface carboxyl groups
by the addition of a mixture of N-hydroxysuccinimide
and 1-ethyl-3-(3-diaminopropyl)carbodiimide. HSF1WT
and HSF1DBD proteins were immobilized until reaching
coupling densities of 12 and 3.5 ng/mm2, respectively.
Immediately before SPR assays, test compounds were dis-
solved at 10 mM in dimethyl sulfoxide (DMSO) and then
diluted into running buffer (10 mM sodium phosphate,
pH 7.5, 150 mM sodium chloride, 0.005% Tween 20, 5%
DMSO). Interaction assays were performed at 25◦C using
a flow rate of 50 l/min. A reference cell was used to
subtract possible nonspecific binding to the chip surface.
Regeneration was with 2 M NaCl.
Analysis of DNA–protein interactions
HeLa cells (1.75 × 106) were seeded in 100 mm dishes
and cultured for 24 h. At that time, the cells were pre-
exposed to indicated doses of compounds or vehicle for
2 h and then heat-treated as detailed above. For elec-
trophoretic mobility gel shift analysis, whole cell extracts
were prepared immediately after heat treatment as previ-
ously described (43,44). Protein concentration in cell ex-
tracts was determined by a Bradford-based protein as-
say (Bio-Rad Laboratories Inc.). Partially complementary
oligonucleotides 5′-GCCTCGAATGTTCGCGAAGTTT-
3′ and 5′-CGAAACTTCGCGAACATTCGAG-3′ were an-
nealed to obtain a probe fragment containing an heat shock
element (HSE) sequence (46). The fragment was labeled
with [-32P]dCTP as earlier reported (47). For typical bind-
ing reactions, 5 l cell extract containing 15 g proteins
were combined with 10 l ‘Kingston’ buffer (4 mMMgCl2,
0.24 mM ethylenediaminetetraacetic acid (EDTA), 24%
(v/v) glycerol, 24 mM HEPES, pH 7.9), 2 l poly(dI-dC)
at 1 mg/ml and 1 l water. After a 15-min pre-incubation
in ice, 2 l of the labeled probe (∼10 000 cpm) were added,
and the reaction was incubated for 15 min at room tem-
perature (RT). Reactions were electrophoresed on 4.5% na-
tive polyacrylamide gels. Dried gels were subjected to au-
toradiography. For chromatin immunoprecipitation (ChIP)
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assays, HeLa cells (4.4 × 106) were seeded in 150 mm
dishes, cultured for 24 h and then treated as described
above. Immediately after heating, cells were fixed with 1%
formaldehyde for 10 min at RT. ChIP assays were per-
formed using the ChIP-IT Express Magnetic Chromatin
Immunoprecipitation kit (Active Motif). Briefly, chromatin
was sheared by enzymatic digestion and immunoprecipi-
tated using a cocktail of rat anti-human HSF1 monoclonal
antibodies (Clones 4B4, 10H4, 10H8; Thermo-Fisher Sci-
entific) or, for control, a rat anti-F4/80 monoclonal an-
tibody (BD Biosciences). Following overnight incubation
at 4◦C in a rotator, immunoprecipitates were collected us-
ing magnetic protein G beads. Chromatin was reverse-
cross-linked, and DNA purified and subjected to real-time
quantitative PCR (qPCR) to detect recruitment of HSF1
to the HSPA1A gene promoter. Specific oligonucleotide
primers were 5′-ATTGGTCCAAGGAAGGCTGG-3′ and
5′-CTCAGGCTAGCCGTTATCCG-3′. qPCR was per-
formed using LightCycler FastStart DNA Master SYBR
Green I and a LightCycler instrument (both from Roche
Applied Science). Samples of not-immunoprecipitated
chromatin were used as input controls for PCR amplifica-
tion.
Analysis of differential gene expression by reverse transcrip-
tion (RT) and qPCR
Z74 cells (3× 105) were seeded in 6-well plates and cultured
for 24 h. At that time, cells were pre-exposed to test com-
pound or vehicle for 2 h and then heat-treated as described
above. After a further incubation for 1 h at 37◦C, total RNA
was prepared using TRI Reagent (Molecular Research
Center, Inc.), following the manufacturer’s instructions.
To quantify the levels of RLUC, HSPA1A, HSPA7 and
DUSP1 mRNA, cDNA was prepared from total RNA
using Transcriptor reverse transcriptase and an anchored-
oligo (dT)18 primer (both from Roche Applied Science).
qPCR was performed as described in the preceding section.
Quantitative expression values were extrapolated from
standard curves, and were normalized to β2-microglobulin
(B2M) values. Specific oligonucleotide primers were:
RLUC: 5′- ATGGGATGAATGGCCTGATA-3′ (F),
5′-TGTTGGACGACGAACTTCAC-3′ (R); DUSP1:
5′ AGGCCATTGACTTCATAGACTCC-3′ (F) and
5′-TGGGAGAGATGATGCTTCGC-3′(R); B2M:
5′-CCAGCAGAGAATGGAAAGTC-3′ (F), 5′-
GATGCTGCTTACATGTCTCG-3′ (R). Levels of
HSPA1A and HSPA7 mRNA were estimated using the
Hs HSPA1A 1 SG QuantiTect Primer Assay and the
Hs HSPA7 FAM 1 QuantiFast Probe Assay, respectively
(both from Qiagen). In some experiments, cDNA was pre-
pared using RLUC (R) and B2M (R) primers. To quantify
the levels of DNAJA4, DNAJB1, DNAJB6, DNAJC28,
EGR1, FOSB, HIST1H1A, HIST1H1B, HIST1H1C,
HIST1H1E, HIST1H2AI, HSPA1L, HSPA6, IER5, JUN,
TADA1 and VHLL mRNA, cDNA was prepared from
total RNA using the High-Capacity RNA-to-cDNA™
Kit (Life Technologies). qPCR was performed using
TaqMan Gene Expression Assays (Life Technologies, see
Supplementary Table S1, Supporting Information, for
Assay IDs) and TaqMan Gene Expression Master Mix.
qPCR reactions were run in an 7900HT Fast Real-Time
PCR System (Applied Biosystems). Sequence Detector
Software 2.4 (Applied Biosystems) was used for data
analysis. A threshold cycle (CT) value was determined
from a log-linear plot of the PCR signal versus the cycle
number. All data were converted to the linear form by
2−CT determination. B2M (Assay ID Hs00187842 m1),
GUSB (Assay ID Hs00939627 m1) and HPRT1 (Assay ID
Hs02800695 m1) were used as endogenous controls.
Microarrays analysis of differential gene expression
HeLa cells (1.75 × 106) were seeded in 100 mm dishes and
cultured for 24 h. The cells were then pre-exposed to test
compound or vehicle for 2 h and heat-treated as described
above. After a further incubation for 1 h at 37◦C, total RNA
was prepared using the RNeasyMini Kit (Qiagen) and pro-
cessed using GeneChip WT PLUS Reagent kit, hybridized
with GeneChip Human Gene 2.0 ST Array and scanned
with a GeneChip scanner 3000 7G (all from Affymetrix).
Raw data were normalized and gene levels analyzed using
the RMA algorithm (Affymetrix Expression Console). For
each experimental condition, three (HeLa) or five (HF73)
RNA replicates corresponding to independent experiments
were processed and analyzed. Fold changes between exper-
imental conditions were calculated as ratios of means of
gene expression signals. Genes with≥1.400- or≤ 0.714-fold
changes were included for further analysis. Gene ontology
analyses were performed using the Database for Annota-
tion, Visualization and IntegratedDiscovery (DAVID; http:
//david.abcc.ncifcrf.gov) (48). Conclusions drawn from mi-
croarray experiments regarding type of regulation were cor-
roborated by RT-qPCR analysis for a representative num-
ber of genes (Supplementary Table S1, Supporting Infor-
mation).
Immunoblotting (WB) experiments
Cellular proteins were extracted with lysis buffer (50 mM
Tris–HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% de-
oxicholate, 0.1% SDS, 1 mM dithiothreitol (DTT), 1 mM
Na3VO4, 1 mM phenylmethylsulfonyl fluoride (PMSF))
supplemented with a protease inhibitor cocktail (Com-
plete). In some experiments, whole cell extracts (43,44) were
used to assess levels of HSF1. Protein concentration in cell
lysates was determined by a Bradford-based protein as-
say. A total of 25 g of proteins were resolved by SDS-
PAGE, transferred to a PVDF membrane and analyzed by
immunoblotting using mouse anti-human HSP72 mono-
clonal antibody C92F3A-5, rabbit anti-human HSF1 poly-
clonal antibody SPA-901 or rat anti-mouse HSF2 mono-
clonal antibody SPA-960 (all from Enzo). A mouse anti-
human GAPDH monoclonal antibody 9484 (Abcam) was
used as a loading control. HSF1 oligomerization was as-
sessed using amine-specific cross-linker ethylene glycol bis-
succinimidyl succinate (EGS) (Pierce). Whole cell extract
(50 g) prepared as previously described (43,44) was in-
cubated with 0.5 mM EGS for 30 min at RT. The cross-
linking reaction was quenched by the addition of 50 mM
glycine/0.025 mM Tris, pH 7.5 and incubation for 15 min
at RT. Proteins were fractionated through a 6% SDS-PAGE
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gel and analyzed by immunoblotting using anti-HSF1 anti-
body SPA-901.
shRNA knockdown
Z74 cells (8 × 104) were seeded in 12-well plates and cul-
tured for 24 h. At that time, the cells were transduced with
HSTF1 shRNA (h) or control shRNA lentiviral particles-A
(both from Santa Cruz Biotechnologies) at multiplicity of
infection (MOIs) of 3, using 5 g/ml polybrene. One day
later, medium containing lentiviral particles was replaced
with fresh medium, and cells were cultured for another
day. Thereafter, cells were incubated for one day in medium
containing 1.3 g/ml puromycin and then trypsinized and
seeded at 1 × 104 cells/well in 96-well plates. At this time,
aliquots of cells were harvested, extracted in lysis buffer
(see the preceding section) and levels of HSF1 and LEXA-
HSF1 assessed by WB. LEXA-HSF1 was detected using
rabbit anti-LexA DNA Binding Region polyclonal anti-
body 14553 (Abcam). After one day of further incubation,
cells were heated at 43◦C for the indicated periods of time
(or not) and then post-incubated for 6 h at 37◦C. FLUC and
RLUC activities were measured as described above.
Immunoprecipitations
CTF135 cells (4.4× 106) cells were seeded in 150mmdishes,
cultured for 24 h, exposed to test compound or vehicle for
2 h and then heat-treated as described above. Cells were ex-
tracted on ice with lysis buffer (50 mM HEPES-KOH, pH
8.0, 100 mM KCl, 2 mM EDTA, 0.1% NP40, 10% glyc-
erol) supplemented with 1 mM DTT, 1 mM PMSF, 0.25
mM sodium orthovanadate, 50 mM -glycerolphosphate,
10 mM NaF, 5 nM okadaic acid, 5 nM calyculin A and
protease inhibitor cocktail (Complete). Cells were lysed by
three cycles of rapid freezing (dry ice-ethanol bath) and
thawing (37◦C water bath). Cell debris was then removed
from cell lysates by centrifugation at 16 000 g for 20 min
at 4◦C. Protein concentrations of extracts were determined
using the protein assay reagent of Bio-Rad and were equal-
ized prior to further analysis. Aliquots of extracts were incu-
bated with 50 l magnetic beads conjugated with 4C5 anti-
DDKmousemonoclonal antibody (OriGene Technologies)
for 2 h at 4◦C with gentle agitation. Immune complexes
were collected by centrifugation and washed once with lysis
buffer and then twice with rinsing buffer (20 mMTris–HCl,
pH 8.0, 2 mM CaCl2). Immunoprecipitated proteins and
aliquots of protein extracts were analyzed by immunoblot-
ting using mouse anti-FLAG monoclonal antibody M5
(Sigma-Aldrich) or rabbit anti-human ATF1 monoclonal
antibody (Abcam).
Cell viability assays
Adherent cells (typically 2 × 104) were seeded in 48-well
plates, cultured for 24 h and then exposed to compound
or vehicle. Suspension cells were seeded in 24-well plates
at a density of 2 × 105 cells/ml and then exposed to com-
pound or vehicle. To achieve resting conditions, WI-38 cells
(105 cells in 48-well plates) were cultured for 2 days prior
to exposure. Viability of cells was investigated using an ala-
mar blue assay (Biosource). Medium of adherent cultures
was removed, and attached cells were incubated in culture
medium containing 10% (v/v) alamar blue dye for 4 h at
37◦C. To investigate viability of suspension cells, 10% (v/v)
alamar blue dye was added directly to the cultures. Medium
was collected and, after laser excitation at 530 nm, emitted
fluorescence at 590 nm was quantified using a BioTek Syn-
ergy4 multimode plate reader (BioTek Instruments). The
criterion used to determine necrosis was loss of membrane
integrity as measured by the uptake of trypan blue (Sigma-
Aldrich). Cells were incubated for 5 min with 0.2% trypan
blue and examined bymicroscopy using a haemocytometer.
Flow cytometry determinations
HeLa cells (3 × 105) were seeded in 6-well plates, cultured
for 24 h and then treated with compound 115 or vehi-
cle. MM1.S cells (106) were seeded in 60-mm dishes and
then treated with compound or vehicle. To determine the
percentage of viable cells exposing phosphatidylserine on
the outer leaflet of the plasma membrane, cells were har-
vested and incubated with Annexin V conjugated to Flu-
orescein isothiocyanate (Annexin V-FITC) and 7-amino-
actinomycin D (7-AAD) following the manufacturer´s in-
structions (Immunostep). Early apoptotic cells were posi-
tively stained with Annexin V-FITC but not with 7-AAD.
To measure loss of DNA, cells were harvested and fixed in
ice-cold 70% ethanol. Fixed cells were collected by centrifu-
gation, incubated for 1 h in PBS containing 50 g/ml pro-
pidium iodide (PI) and 100 g/ml RNase, and then ana-
lyzed by flow cytometry. Cells exhibiting sub-G1 PI incor-
poration were considered apoptotic. Cells were analyzed by
flow cytometry using a FACSCalibur flow analyzer and em-
ploying the CellQuest Pro software (BD Biosciences).
Statistical analysis
Unless indicated otherwise, data are presented as means,
or means ± SD, of at least three independent experiments.
Statistical tests of differential gene expression assessed by
microarray analyses and validation by RT-qPCR were per-
formed using the limma software (49). The differences be-
tween experimental groups H, C and HT were tested using
unpaired t-tests and Benjamini–Hochberg method for mul-
tiple comparison correction. Other experiments were ana-
lyzed using theGraphPad Prism v6 software, using one-way
ANOVA followed by Dunnett’s multiple comparison test.
The criterion for significance in statistical analyses was set
at P ≤ 0.05.
RESULTS
Initial virtual screen to find HSF1 binders
No structure for an entire HSF/HSF1molecule was known
when this study was initiated. However, structural informa-
tion existed for HSF DNA-binding domains. Eleven struc-
tures from yeast (9) and Drosophila (2) were available in
the Brookhaven Protein Databank. Sequence comparison
between Drosophila HSF and human HSF1 showed 57%
sequence identity and 72% sequence similarity. Using a
snapshot from the Drosophila NMR structures (1HKT), a
6 Nucleic Acids Research, 2017
comparative model of the human HSF1 DNA-binding do-
main was generated. Using this model, four potential cav-
ities were predicted to be large enough to accommodate
small drug-like molecules. Based on the potential interac-
tions with residues which line the putative binding pockets,
nine three-point pharmacophores were defined and were
used to virtually screen a library of 300 000 commercially
available lead-like molecules, resulting in the selection and
purchase of ∼2000 compounds to constitute a biased sub-
library.
Development of a cell-based assay for human HSF1 DNA-
binding domain binders, screen of the biased sublibrary and
discovery of compound IHSF001
We were interested in any molecule capable of binding the
HSF1 DNA-binding domain and affecting the function of
the transcription factor, not only in molecules that interfere
with DNA-binding (three of the four predicted cavities be-
ing distant from the area involved in nucleic acid contact).
Consequently, we wished to screen the biased sublibrary
employing an assay that reported HSF1-mediated gene ex-
pression rather than DNA-binding. Development of a suf-
ficiently discriminating cell-based assay was confounded by
the integrated nature of the HSR system. A straightfor-
ward assay based on expression of an HSF1-responsive
gene likely would have captured many compounds that af-
fect HSF1 activity indirectly such as inhibitors of kinases,
activators of phosphatases, enhancers of protein degrada-
tion, inhibitors of growth signaling and inhibitors of HSF1
mRNA stability. To exclude such indirectly acting com-
pounds from the screening results to the best extent pos-
sible, advantage was taken of the modular nature of HSF1,
which permits replacement of the HSF1 DNA-binding do-
main with an unrelated DNA-binding domain, to create a
chimeric transcription factor whose activity is regulated like
that of HSF1 but that binds to a different target promoter
(43,44). Stable cell line Z74 was developed that was capa-
ble of reporting the effects of a compound on the activities
of both wild type HSF1 and chimeric HSF1. In order to be
considered a true hit, a compound would have to inhibit the
activity of wild typeHSF1 but not/less chimericHSF1 (that
lacks an HSF1 DNA-binding domain).
Z74 cells contain an inserted gene for chimeric transcrip-
tion factor LEXA-hHSF1 under the control of a CMV
early promoter, an FLUC gene driven by a promoter re-
sponsive to the latter chimeric transcription factor and an
RLUC gene functionally linked to an HSP70B (HSPA7)
heat shock gene promoter and therefore controlled by en-
dogenous HSF1 (Figure 1A). Both reporter genes are ac-
tivated by heat shock in a similar dose-dependent fashion
(Figure 1B and C). Knockdown by shRNA confirmed that
the induced expression of both reporters is dependent on
HSF1/chimeric HSF1, although LEXA-hHSF1 appeared
to be depleted to a lesser degree than HSF1, and expres-
sion of its reporter gene (FLUC) to be only effectively re-
duced under moderately severe stress conditions (Figure
1D). Screening of the sublibrary discovered compound 001
which inhibited RLUC but not FLUC expression in heat-
treatedZ74 cells (Figure 2A) andwhich, therefore, appeared
to act specifically through theHSF1DNA-binding domain.
(Compound 001 and active derivatives are also referred to
herein as HSF1 inhibitors or IHSF.) In a confirmatory ex-
periment, IHSF001 was shown to inhibit FLUC expression
in a cell line containing an HSPA7 promoter-driven FLUC
gene (data not shown).
Analysis of structure–activity relationships
Replacement of the thiazole group present in IHSF001 by
other five- or six-membered aromatic cycles was examined.
Selected results are shown in Table 1A.We found that while
some ring substitutions exhibited inhibitory activity in Z74
cells, none showed increased activity over IHSF001. There-
fore, the thiazole ring was maintained, and effects of substi-
tution at positions R1 and R2 were investigated. Modifica-
tion at positions R1 and/or R2 often enhanced inhibitory
activity, especially whenR2 is an aromatic group (Table 1B).
Pyridyl addition at R2 increased inhibitory activity most ef-
fectively (compound 058; see also Figure 2A). Notable ex-
ceptions when R1 was cyclopropyl (compound 053) or car-
boxylic acid (compound 106) suggest that non-planar or
negatively charged groups at this position are detrimental
to inhibitory activity. Introduction of a methyl group at the
R3 position as in compound 070 significantly enhanced in-
hibitory activity compared to IHSF001 (Table 1C). However,
larger groups atR3 resulted in little or no inhibitory activity.
Whether the exocyclic C = C double bond was an essential
feature to retain activity was also considered. The double
bond was modified in two ways. First, it was replaced by the
more-flexible C-C single bond to give compound 032 (Ta-
ble 1D). This compound was devoid of inhibitory activity.
Second, structural rigidification of rotatable bonds has been
practiced inmany systems and has been found to contribute
to higher specificity and potency,metabolic stability and im-
proved bioavailability (ref. 50 and references cited therein).
The scaffold under investigation was rigidified by replacing
the exocyclic C = C double bond with an aromatic bond as
in compound 071. The new aromatic ring in compound 071
contains a nitrogen atom ‘ortho’ to the secondary amine in
order to mimic the replaced amide carbonyl oxygen. How-
ever, this change also resulted in the loss of inhibitory activ-
ity. Substitution at the exocyclic C = C double bond of the
scaffold was also investigated. Modification at either R4 or
R5 resulted in complete loss of activity as shown by com-
pounds 111 and 085, respectively (Table 1C).
Replacement of the ethyl ester with methyl or isopropyl
esters, a ketone or an ether produced inhibitors with re-
duced potencies (compounds 027, 028, 095 and 097 in Ta-
ble 1E). Substitution of the ester with an amide also re-
sulted in reduced activity (compound 030). Replacement of
the ester with the corresponding acid resulted in inactive
compound 004, perhaps owing to the reduced ability of a
charged molecule to pass the cell membrane. Out of con-
cern that an ester may not be very stable in vivo and may be
rapidly hydrolyzed to the inactive acid, we were keen to find
a replacement for the ester that would be potentially more
stable but retained most of the structural properties of the
ester. Compound 001 had been included in the sublibrary
as a potential binder of predicted cavity A within the HSF1
DNA-binding domain (defined by Val70, Leu73, Asn74,
Phe78, Arg79, Lys80, Thr97, Glu98 and Phe99). Based on
Nucleic Acids Research, 2017 7
Figure 1. Characterization of Z74 cells. (A) Z74 cells harbor an RLUC gene that is linked to an HSPA7 gene promoter. The latter promoter is responsive
to endogenous human transcription factor HSF1 (eHSF1). Z74 cells also contain a CMV promoter-driven gene for chimeric transcription factor LEXA-
HSF1 as well as a FLUC gene controlled by a promoter responsive to LEXA-HSF1. Transient heat stimulates the transcriptional activities of eHSF1 and
LEXA-HSF1, resulting in increased expression of the FLUC and RLUC genes. (B and C) RLUC and FLUC activities in Z74 cells increase as a function
of the intensity of their heat exposure. Cells were left untreated (−), were heated (HS) at 42◦C for the indicated periods (B) or were heated at different
temperatures for 30 min (C). RLUC (dark columns) and FLUC (light columns) activities were determined 6 h after heat treatment. *P < 0.05; comparing
to RLUC activity of untreated cells; #P < 0.05; comparing to FLUC activity of untreated cells. (D) Ratios between RLUC and FLUC activities in HSF1
shRNA and control shRNA-expressing cells heated at 43◦C for the indicated periods. Levels of HSF1 and LEXA-HSF1 were assessed byWB (on the left).
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Figure 2. (A) Inhibitory activities of IHSF001, IHSF058 and IHSF115 in the Z74 screening assay. Z74 cells, exposed to the inhibitors at the indicated concen-
trations for 2 h, or exposed to vehicle (−), were heat-treated (HS) at 43◦C for 30 min. After 6 h of post-incubation at 37◦C (in the continued presence of the
inhibitors), RLUC (dark columns) and FLUC (light columns) activities were determined. *, #: P< 0.05; comparing to heat-treated cells exposed to vehicle.
(B–D) Docking of IHSF115 into predicted cavity A of human HSF1. (B) Images showing the local environment of the R3-methyl in docked IHSF115. The
residues in close proximity to the methyl group are V70, K80, T97 and F99, which residues partly define the cavity A binding site. The surface shows that
there is potentially very limited room for growth at the R3 position. (C) The residues in close proximity to the buried six-membered dihydro-oxazine ring
and scaffold double-bond are shown. The surface also reveals that there is limited potential for growth from the double bond. (D) Schematic represen-
tation of residues in close proximity to IHSF115. (E and F) Docking of IHSF001 into predicted cavity A of human HSF1 (E). Images showing the local
environment of the R3-unsubstituted amide NH in docked IHSF001. (F) Residues in close proximity to the ethyl ester group and scaffold double-bond. (G)
SPR sensorgrams documenting interactions between IHSF115 or IHSF058 and (His-tagged) recombinant HSF1WT or HSF1DBD proteins.
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Table 1. Structure–activity relationships
IC50 values represent concentrations of compounds required for 50% inhibition of heat-induced RLUC activity in Z74 cells. IC50 values were estimated
by extrapolation from two data points exhibiting >50% inhibition and <50% inhibition, respectively. Representative values are shown. For several key
compounds, IC50 values were determined from full activity/concentration curves, and SD values were estimated. ND: no activity detected.
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the hypothesis that compound 001 in fact binds in the lat-
ter cavity, a docking experiment was carried out that com-
pared compound 001 with virtual compounds in which the
ester had been replaced with five- or six-membered rings.
Results suggested that rings of the latter size could be ac-
commodated by the cavity (see the docking experiment dis-
cussed below). A set of compounds with different ester re-
placements was synthesized and tested for inhibitory ac-
tivity. Whereas most replacements resulted in compounds
with lower inhibitory activity than compound 001, a par-
tially unsaturated heterocycle produced a compound with
considerably better inhibitory activity (compound 090).
Finally, we combined those individual modifications that
had most effectively improved inhibitory activity. These
modifications included addition of a 3-Py at position R2, a
methyl group at R3 and substitution of the carboxylate es-
ter with the partially unsatured dihydro-oxazine heterocycle
of compound 090. The resulting compound, IHSF115, was
clearly a better inhibitor in Z74 cells than lead compound
001 or the compounds containing the individual modifica-
tions (Table 1F). IHSF115 had substantial activity in the high
nanomolar/low micromolar range (see also Figure 2A).
A docking study was conducted to identify potential
binding modes of IHSF115 and rationalize the observed im-
provement in activity. The docking program ‘GOLD’ (51)
was employed for docking IHSF115 into cavity A. Up to
5000 docking solutions were allowed, in which each dock-
ing had to deviate from the previously generated solutions
by a minimum of 2.0A˚ RMSD with respect to heavy atoms.
This approach allowed the exhaustive exploration of the po-
tential binding modes of IHSF115 in cavity A. The result-
ing dockings were then analyzed; a valid pose needed to (i)
place the R3 substituent into a position where very small
alkyl groups are tolerated but larger groups would clash
with the binding site, (ii) place both R4 and R5 positions
of the scaffold in such a way as to not accommodate any
potential substituents at these positions and (iii) place the
partially unsaturated six-membered heterocycle into a small
pocket, thus not tolerating significant growth of the group.
Docking of molecule 115 into cavity A yielded an interest-
ing binding mode, which largely agreed with the structure–
activity results (Figure 2B–D). The docking mode has the
following notable features: the N-Me group is buried into a
well-defined hydrophobic sub-pocket defined mostly by the
side-chains of Val70, Lys80, Thr97 and Phe99. The bulky
sulfur atom in the thiazole ring also points toward this
pocket. The partially unsaturated six-membered heterocy-
cle (5,6-dihydro-4H-1,3-oxazine) is accommodated into an-
other sub-pocket, but appears to make no formal hydrogen
bonds with the homology model. However, the group could
potentially interact with the side chain of Asn74 and, fur-
ther away (about 5.0A˚), the side chain of His83 through a
water-mediated interaction. For the sake of completeness,
an analogous docking experiment conducted with IHSF001
is reported in Figure 2E and F.
Further investigation focused on best inhibitor IHSF115.
However, several experiments also included IHSF058 as an
example of compounds that displayed properties not seen
with IHSF115.
SPR was used to confirm that the inhibitors of hu-
man HSF1 function interact directly with the transcrip-
tion factor and, more specifically, its DNA-binding do-
main. Recombinant human HSF1 or a recombinant DNA-
binding domain fragment of human HSF1 served as lig-
ands. As revealed by the SPR sensorgrams in Figure 2G,
both compounds tested, i.e. IHSF058 and IHSF115, inter-
acted in a dose-dependent fashion with both full-length
HSF1 (HSF1WT) and the HSF1 DNA-binding domain
(HSF1DBD) fragment. These results provide strong evi-
dence that the compounds directly bind the HSF1 DNA-
binding domain. It is noted that evidence for interaction
was obtained at compound concentrations (15.6 M and
higher) that were above those that cause inhibition of in-
duced RLUC expression in Z74 cells. This difference in sen-
sitivity may be due to conformational constraints imposed
by the method of immobilization of the polypeptides on the
sensor chips (amine coupling). Alternatively, or in addition,
the recombinant HSF1WT and HSF1DBD fragments that
lack all critical modifications of HSF1 as well as its normal
cover of chaperones and other cofactors may not have been
able to acquire a quasi-native and fully competent confor-
mation.
Mode of action of HSF1 inhibitors
In a first set of experiments, cultures of Z74 cells were ex-
posed to different concentrations of IHSF058 or IHSF115,
heat-treated and post-incubated for 1 h. Total RNA was
isolated, and poly-adenylated RNA quantified by RT-
qPCR. Exposure of the cells to the compounds resulted
in a dose dependent reduction of transcript levels of
the HSPA7 promoter-driven RLUC gene (Figure 3A, left
graph). IHSF115 was somewhat more effective than IHSF058
in inhibiting accumulation of transcripts. It is noted that
substantial effects already occurred at 1 M concentra-
tions. Similar results were obtained when totalRLUCRNA
was quantified (Figure 3A, right graph). We take these data
to reflect effects of the inhibitors on HSF1-mediated HSP
promoter-driven gene transcription. Although we have not
investigated effects at the level of transcript stability, the
fact that the compounds were designed to bind to HSF1
and were shown to do so renders this possibility some-
what remote. Analogous dose-dependent inhibitory effects
on transcript accumulation were observed for the endoge-
nous HSPA1A and HSPA7 genes, although larger com-
pound concentrations were needed to achieve comparable
inhibition effects to those seen for the RLUC gene, pos-
sibly owing to some compensatory mechanism(s) (Figure
3B and C). Heat-induced accumulation of inducible HSP72
(mainly products of the HSPA1A and HSPA1B genes) was
assessed by WB (Figure 3D). Inhibitory effects of IHSF115
were observable at 3.125 M and were substantial at 6.25
M. IHSF058 was less effective than IHSF 115.
To examine whether the inhibitors affected sequence-
specific DNA-binding of HSF1, extracts were prepared
from HeLa cells that had been exposed for 2 h at 37◦C
to different concentrations of IHSF058, IHSF115 or vehicle
and then heat-treated for 30 min at 43◦C. Electrophoretic
mobility shift assay (EMSA) using an HSE oligonucleotide
probe showed that IHSF058, but not IHSF115, prompted a
dose-dependent reduction of DNA-binding activity (Fig-
ure 4A, top). An anti-HSF1WB revealed a dose-dependent
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Figure 3. (A–C) Inhibitory activities of IHSF058 and IHSF115 assessed at the transcript level by RT-qPCR. Z74 cells, exposed to the inhibitors at the
indicated concentrations for 2 h, or exposed to vehicle (−), were heat-treated (HS) at 43◦C for 30 min and post-incubated at 37◦C for 1 h (in the continued
presence of inhibitors). (A) Relative RLUCmRNA (left graph) and RLUC total RNA (right graph) levels. (B) RelativeHSPA7mRNA levels. (C) Relative
HSPA1AmRNA levels. *P < 0.05; comparing to heat-treated cells exposed to vehicle. (D) Inhibition of HSP72 expression assessed by WB. Z74 cells were
treated as under (A–C), except that post-incubation at 37◦C was for 6 h.
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Figure 4. On themechanism of action of IHSF. (A) Effects onHSF1DNA-binding ability, stability and oligomerization. Analyzed were extracts fromHeLa
cells that were vehicle-treated or pre-treated for 2 h with the indicated concentrations of IHSF058 or IHSF115 and then exposed to 43◦C heat for 30 min
(HS). Top: HSF1 DNA-binding ability determined by EMSA. The arrows indicate the positions of the major HSF1–HSE probe complexes. Middle: HSF1
immunoblot. GAPDH served as loading control. Bottom: HSF1 immunoblot after EGS cross-linking of HSF1 in oligomers. The positions of pre-stained
molecular weight marker proteins (MW, in thousands) are indicated to the left. Asterisks indicate the positions of monomeric and trimeric HSF1. (B)
Top: effects on the recruitment of HSF1 to the HSPA1A promoter. HeLa cells, exposed to IHSF058 or IHSF115 at 12.5 M, or exposed to vehicle (−),
were heat-treated (HS) at 43◦C for 30 min and then processed for ChIP using anti-HSF1 or anti-F4/80 LR (control) antibodies. *P < 0.05; comparing to
heat-treated cells exposed to vehicle. Bottom: anti-HSF1WB of extracts from cells exposed to identical conditions. (C) Co-immunoprecipitation of ATF1.
Left and right halves show results from independent experiments. CTF135 cells expressing a C-terminally FLAG-tagged HSF1 were vehicle-treated (−) or
pre-treated with 12.5 or 25 M IHSF115, heat-treated (HS) at 43◦C for 30 min and then processed for immunoprecipitation with an anti-FLAG antibody.
Immunoprecipitates (IP:FLAG) and aliquots of extracts (input) were analyzed by anti-FLAG and anti-ATF1 immunoblot.
destabilization ofHSF1 by compound 058 (Figure 4A,mid-
dle). It appeared that this effect can account for the reduced
HSE DNA binding observed with extracts from IHSF058-
exposed cells. The most potent inhibitor, IHSF115, did not
display this property. That IHSF115 (and IHSF058 apparently
as well) did not inhibit HSF1DNA-binding activity implied
that heat-induced homo-oligomerization of HSF1 was also
not affected by the compounds. To verify this, aliquots of
the same extracts that were tested in the above EMSAassays
were exposed to EGS to cross-link HSF1 oligomers and
re-analyzed by anti-HSF1 WB. No impairment of HSF1
oligomerization by IHSF115 or IHSF058 could be observed
(Figure 4A, bottom). To find out whether the compounds
reduced HSF1 DNA binding in the chromatin context, we
carried out ChIP experiments on similarly treated HeLa
cells (at compound concentrations of 12.5 M). Cultures
were processed as described in ‘Materials and Methods’
section. DNA fragments precipitated by HSF1 antibodies
were amplified by qPCR using primers that delineate a pro-
moter segment of theHSPA1A gene including the proximal
HSE sequence (HSF1 target sequence) and the TATA box
sequence. IHSF115 was found not to cause any reduction
in HSF1 binding (Figure 4B, top). However, significantly
decreased promoter occupancy was observed in IHSF058-
treated cells. Again, this decrease could be readily explained
as an effect of destabilization of HSF1 by the compound
as evidenced by an anti-HSF1 WB of extracts from cells
exposed to identical conditions (Figure 4B, bottom). It is
noted that the absence of an effect of IHSF115 on promoter
occupancy also implies that the compound does not inter-
fere with nuclear import of HSF1 in a significant fashion.
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By way of elimination, the above analysis suggests that
HSF1 inhibitors (at least those of the IHSF115 type) af-
fect the transactivation function of HSF1. It is known
that ATF1/CREB regulates the stress-induced HSF1 tran-
scription complex and mediates the recruitment of mam-
malian HSF1 to its target promoters (19). ATF1/CREB in-
teracts with the HSF1 DNA-binding domain. We investi-
gated whether IHSF115 was capable of interfering with the
HSF1–ATF1 interaction. Use was made of a HeLa-derived
cell line that stably expresses a C-terminally FLAG-tagged
HSF1. Cultures were heat-treated for 30 min at 43◦C in the
presence or absence of IHSF115, extracts were prepared and
taggedHSF1was immunoprecipitated using an anti-FLAG
antibody. WB analysis of immunoprecipitates revealed that
IHSF115 dramatically reduced the HSF1–ATF1 interaction
(Figure 4C). Based on this finding, we suggest that IHSF115
interferes with the formation of ATF1-based transcription
complexes that is instrumental in heat-induced transcrip-
tion of HSF1 target genes.
Using inhibitor IHSF115 to probe the human heat shock re-
sponse (HSR) at the transcript level
HeLa cells were either subjected to a heat treatment at
43◦C/30 min and then post-incubated at 37◦C for 1 h or
were maintained at 37◦C. The latter relatively mild heat
shock conditions (employed also in most other experi-
ments of the present study) were chosen to avoid stress-
induced perturbations to the best extent possible. Exposure
to IHSF115 began 2 h before heat treatment. RNA was iso-
lated and analyzed by hybridization to Affymetrix microar-
rays. It is noted that WB analysis of similarly treated cells
revealed that HSF1 was not destabilized by IHSF115 (Figure
5A, lower two blots). We restricted our analysis to protein-
coding genes (except for HSPA7) whose transcript levels
changed by at least 1.4-fold (in either direction) after heat
treatment. This resulted in sets of 667 heat-induced and 406
heat-repressed genes (column H/C in Supplementary Table
S2, Supporting Information; H: heat-treated; C: control-
treated). For comparison purposes (see below), the numbers
given are for the 511 most highly heat-induced genes. The
heat-induced increases in transcript levels of many of these
genes were inhibited partially to completely by IHSF115
(HT/H ratios significantly lower than 1, and (HT-C)/(H-
C) ratios lower than 1; see Supplementary Table S2; HT:
heat-treated and IHSF-exposed). Based on the latter findings
of inhibition, 328 heat-induced genes (64.2%) were classi-
fied as positively regulated by HSF1. Values significantly
lower than 1 in column HT/C (and negative (HT-C)/(H-
C) values) were observed for 19 of these genes, suggesting
that their expression in HeLa cells was supported by HSF1
even in the absence of a stress. The transcript levels of seven
genes (1.4%) had risen in heat-treated cells in the presence of
IHSF115 (HT/H ratios significantly higher than 1, and (HT-
C)/(H-C) ratios higher than 1). These heat-induced genes
appeared to be negatively regulated by HSF1. Finally, 176
heat-induced genes (34.4%) were considered not-regulated
by HSF1 (HT/H ratios not significantly different from 1).
Results obtained for the 50 most highly heat-induced genes
are visualized in Figure 5B (columns ‘HeLa’). The fraction
of genes that are positively regulated by HSF1 may be con-
siderably higher than is suggested by the above estimate of
64.2% and may reach a figure as high as about 80%. Per-
centages of IHSF115-inhibited genes within groups of 100
heat-induced genes with decreasing heat inducibility (H/C
ratios equal to or greater than 2.822, 2.022, 1.733, 1.610,
1.505, 1.432 and 1.401 for the remainder group of 67 genes)
were found to decrease essentially monotonously from 75 to
43% (Figure 5C, top left). The best explanation for this un-
usual correlation appears to be that, with decreasing heat
induction, partial inhibition by IHSF115 increasingly fails
to reach statistical significance. Thus, in groups with in-
creasingly smaller heat inducibility, the number of HSF1-
regulated genes that fail to be recognized and, consequently,
apparent average efficacy of IHSF inhibition increase (see
Figure 5C, top right). Corresponding data for cell lineHF73
(see below) are presented in Figure 5C, bottom graph.
A very different picture emerged for the heat-repressed
genes (see Figure 5E, columns ‘HeLa’, for a visualization
of effects seen for the 50 most highly heat-repressed genes).
Most of these genes (292, representing 71.9% of repressed
genes) were classified as not regulated by HSF1 (HT/H ra-
tios not significantly different from 1). Perhaps, these genes
are subject to a global repression mechanism(s). Neverthe-
less, IHSF115 caused partial to near complete relief from re-
pression in 87 (21.4%) of the heat-repressed genes (HT/H
ratios significantly higher than 1, and (HT-C)/(H-C) ratios
lower than 1; Supplementary Table S2). These genes are
considered negatively regulated by HSF1. That exposure of
cells to IHSF115 essentially reverses the repressive effect of
heat treatment on the expression of certain genes strongly
suggests that the inhibitor does not exert a generalized in-
hibitory effect on transcription. As a corroboration, expo-
sure of HeLa cells transfected with constitutively expressed
luciferase genes to IHSF115 for 6 h had only amarginal effect
on reporter gene expression (not shown). A small number
of heat-repressed genes (27 (6.7%)) appeared to be positively
HSF1-regulated.
An earlier genome-wide gene expression microarray
study inHeLa cells had reported 511 heat-induced and 1305
heat-repressed genes (29). HSF1-regulated genes were iden-
tified by comparing heat regulation in HSF1-depleted and
not-depleted cells. The findings of the latter study are sum-
marized in Table 2. In the present study, HSF1 regulation
was revealed by positive or negative effects of IHSF115 on
gene transcription. To compare our data with those of the
earlier study, we added in Table 2 information on the 511
most highly heat-induced genes and all heat-repressed genes
of the present study. The results of the two studies are sur-
prisingly different. The earlier study identified 137 genes
that were positively regulated byHSF1 (26.8%). Similar fre-
quencies were reported in a recent study in mouse embryo
fibroblasts (52). Our study suggests that the heat induction
of at least 328 of the 511 genes (64.2%) was mediated by
HSF1. Thus, 2.4-times as many positively HSF1-regulated
genes were identified based on the immediate effects of a
specific HSF1 inhibitor than based on the delayed effects
of HSF1 depletion. Among the heat-repressed genes, simi-
lar estimates of the fraction of HSF1-repressed genes were
obtained from inhibition of HSF1 transcriptional activity
(21.4%) and HSF1 depletion (20.8%). Numbers of genes
with complex regulation were substantially smaller when
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Figure 5. Transcriptome analyses. (A) Top: WB showing expression of HSF1 and HSF2 in HeLa and HF73 cells, respectively. Lower blots: HeLa or HF73
cells were vehicle-treated or exposed to 12.5 or 25 M IHSF115 for 2 h, heat-heated at 43◦C for 30 min and post-incubated at 37◦C for 1 h or vehicle-treated
and incubated at 37◦C for 3.5 h. Extracts were analyzed for HSF1 levels. (B and E) HeLa and HF73 cells were similarly treated (at 25 M IHSF115), and
RNA was extracted and analyzed using Affymetrix microarrays. HT: heat-treated and IHSF115-exposed; H: heat-treated; C: vehicle-treated. (B) Heatmaps
showing heat inducibility (H/C) in the left columns and effects of IHSF115 on heat-induced expression (IHSF115 effects: (HT-C)/(H-C)) in the right columns
for the 50 most highly heat-induced genes in HeLa cells. *P < 0.05 between HT and H. (C) Left: fractions of HSF1-regulated genes in groups of 100 heat-
induced genes. Right: IHSF115 Effects ((HT-C)/(H-C)). See the ‘Results’ section for further explanations. *P < 0.05; comparing to group 1–100. (D) HSE
sequences. Top: consensus (gene-proximal) HSE derived from a group of 30 heat-induced, HSF1-regulated genes. Bottom: consensus HSE derived from
a group of classical heat shock genes. The logograms were generated at http://weblogo.berkeley.edu. (E) Heatmaps as in (B), but for the 50 most highly
heat-repressed genes in HeLa cells. (F) GO analyses (biological processes). Light green: heat-induced, positively HSF1-regulated genes; red: heat-repressed,
negatively HSF1-regulated genes.
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estimated from effects of IHSF115 instead of from differ-
ences in gene expression between HSF1-depleted and con-
trol cells. This concerns heat-induced genes whose activ-
ity is limited by active HSF1 (1.4 versus 7.4%), and heat-
repressed genes whose activity appears to be positively af-
fected by active HSF1 (6.7 versus 17.7%).
HeLa cells express HSF2, another member of the HSF
family. HSF2 is known to bind to HSE sequences in the
promoters of many heat-regulated genes as well as to form
heterooligomeric complexes with HSF1 (53,54). While ap-
parently not able to function as a transcription factor
on its own, HSF2 was found to enhance/reduce HSF1-
mediated expression of major HSP genes (55,56). To find
out whether HSF2 modulates IHSF effects or may even be
required for these effects, we used CRISPR technology to
obtain a HeLa-derived cell line deficient for HSF2 and re-
peated the microarray analysis (Figure 5A, top blot). We
found 434 heat-induced and 220 heat-repressed protein-
coding genes in HSF2-deficient line HF73 (column H/C
in Supplementary Table S3, Supporting Information). Of
the 511 most highly heat-induced genes in HeLa cells, 407
were less highly heat-induced in HF73 cells, 26 were more
highly heat-induced and 78 were unchanged (<10% change
in the H/C ratio) (see Supplementary Table S4, Support-
ing Information). This finding is consistent with the notion
that HSF2 is an important cofactor of HSF1 that gener-
ally affects heat-induced gene expression. Based on their
transcriptional responses to IHSF115, 267 of the 434 heat-
induced genes of HF73 cells (61.5%) were considered to
be regulated by HSF1 (Table 2; see also Figure 5B and
E, columns ‘HF73’). This frequency is similar as that ob-
served in HeLa cells, where 335 of 511 heat-regulated genes
(65.6%) were HSF1-regulated. Clearly, IHSF function is not
dependent on HSF2. Closer inspection of results revealed
remarkable qualitative changes in the regulation of heat-
induced genes that may have been caused by the absence
of HSF2. Twenty-one heat-induced genes that were posi-
tively HSF1-regulated (3) or unregulated (18) in HeLa cells
showed as negatively HSF1-regulated in HF73 cells (Sup-
plementary Table S4). Moreover, 50 genes that were pos-
itively regulated in HeLa cells were found unregulated by
HSF1 and 15 genes that had been unregulated in HeLa cells
positively HSF1-regulated in HF73 cells. Among the 220
heat-repressed genes identified in HF73 cells, 97 (44.1%)
appeared to be HSF1-regulated (Table 2). The fractions
of both negatively and positively regulated heat-repressed
genes were increased in HF73 cells compared with HeLa
cells.
HSF1 acts through HSE sequences in the promoters of
the genes it controls. The ability to identify HSF1-regulated
genes by their susceptibility to an HSF1 transcriptional in-
hibitor provided us with an opportunity to define an HSE
consensus sequence based on a functional criterion. Such
a sequence derived from a group of 30 IHSF115-inhibited
genes exhibiting different levels of heat inducibility is shown
in Figure 5D (top logogram). It contains two complete
NGAAN modules of which one is less prominent than the
other. An HSE consensus sequence obtained from a group
of classical heat shock genes looks notably different, featur-
ing four or five modules, of which three are similarly promi-
nent (bottom logogram). The latter sequence resembles a
consensus sequence that had been derived from an analysis
of in vivo binding sites of HSF1 (30). It therefore appears
that somewhat degenerate HSE sequences remain capable
of conferring heat regulation on an associated gene, even
though binding of HSF1 to such elements may not be de-
tected by currently usedmethods. The above group of 30 ex-
ample genes was also searched for transcription factor bind-
ing sites known to be associated with heat-regulated genes
(52). Binding sites for AP1, SRF, YY2 and ELF1 were each
present in about 60% of the genes. The average distance of
these elements from the transcription start site was gener-
ally similar as that of the promoter-proximalHSE sequence.
The present study classified a far greater proportion of
heat-induced genes as positivelyHSF1-regulated genes than
the most relevant previous study (29). To find out whether
we could discover additional gene categories that had not
been associated previously with regulation by HSF1, we
carried out a GO analysis using the David bioinformatics
resources (48). The range of biological processes that in-
volve positively HSF1-regulated genes uncovered by this
analysis is represented in Figure 5F. Categories identified
include proteotoxic stress-related categories such as ‘pro-
tein refolding’, ‘response to unfolded proteins’, ‘cellular re-
sponse to heat’ and ‘protein folding’. However, they also
include categories such as ‘response to hormone stimu-
lus’, ‘skeletal muscle differentiation’, ‘response to cAMP’,
‘response to lipopolysaccharide’, ‘response to mechanical
stimulus’, ‘negative regulation of cell growth’, ‘regulation
of transcription from Pol II promoters’ (positive and neg-
ative) and ‘regulation of cell cycle’. Prominent categories
of negatively HSF1-regulated genes are ‘regulation of tran-
scription’ and ‘nucleosome assembly’. The complete results
of this analysis are shown in Supplementary Table S5, Sup-
porting Information.
IHSF impair the viability of cancer cells
Cancer cells are dependent on HSF1 for growth as has been
demonstrated by siRNAknockdown (31). Compounds that
inhibit HSF1 function are expected to have analogous ef-
fects on cancer cells. We assessed the viability of HeLa cells
exposed for 96 h to different concentrations of IHSF001, 058
and 115 using an alamar blue assay (Figure 6A). Viability
decreased in a dose-dependent fashion with IHSF115 being
considerably more effective than IHSF058 and 001. The rel-
ative cytotoxicity of the compounds is approximately in line
with their respective strengths as inhibitors of HSF1 activ-
ity. Subsequently, we explored effects of IHSF115 on via-
bility in a panel of different human cancer cell lines (Fig-
ure 6B). HSF1 has been described as being required for
optimal p21 expression and p53-mediated cell cycle arrest
in response to genotoxins, suggesting that the factor may
also play a p53-dependent pro-apoptotic function (57). To
test whether responsiveness to IHSF115 depended on p53,
cell lines of different p53 status were included in the panel.
Results showed that all cell lines suffered a loss in viabil-
ity upon exposure to IHSF115, although sensitivity varied
widely. No systematic effect of loss of p53 function could be
detected. HSF1 is the master regulator of inducible HSP ex-
pression, and HSPs are key components of the cell’s mecha-
nism for proteostasis maintenance. That levels of activated
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Table 2. Heat regulation by HSF1––results obtained based on HSF1 depletion or HSF1 inhibition
Regulation by HSF1 RNA levels after heat treatment
Increased Decreased
Cell type HeLa HeLa HF73* HeLa HeLa HF73
No regulation 336 (65.8%) 176 (34.4%) 167 (38.5%) 802 (61.5%) 292 (71.9%) 123 (55.9%)
Negative regulation 38 (7.4%) 7 (1.4%) 39 (9.0%) 272 (20.8%) 87 (21.4%) 65 (29.6%)
Positive regulation 137 (26.8%) 328 (64.2%) 228 (52.5%) 231 (17.7%) 27 (6.7%) 32 (14.5%)
HSF1 siRNA
depletion**
IHSF115 inhibition (present study) HSF1 siRNA
depletion**
IHSF115 inhibition (present study)
*HSF2-deficient HeLa-derived line.
**The depletion data are from ref. 29.
Figure 6. (A) Viability of HeLa cells that had been exposed for 96 h to the indicated concentrations of IHSF001, IHSF058 or IHSF115, or to vehicle (−).
*P < 0.05; comparing to cells exposed to vehicle. (B) Heatmap summarizing viability data obtained for different cell lines. AML: acute myeloid leukemia.
MPNST: malignant peripheral nerve sheath tumor. Wt: wild-type. Mut: mutated. EC50: dose causing a 50% reduction in viability.
HSF1 tend to be elevated in cancer cells suggests that these
cells may require elevated levels of HSPs for coping with an
increased load of mutated proteins with non-native confor-
mations (30,38). An increased requirement for chaperones
may be readily rationalized for cells whose growth is driven
by proteins expected to be conformationally compromised
such as fusion kinases or mutation-activated kinases. Re-
sults showed that EML4-ALK fusion kinase-expressing cell
lines NCI-H3122 and NCI-H2228 or mutation-activated
EGFRkinase-expressing lineNCI-H1975 are not especially
responsive to IHSF115. Proteostasis maintenance appears to
be particularly challenged in multiple myeloma cells that
are highly sensitive to inhibition of proteasome function
(58). We found that multiple myeloma lines consistently ex-
hibited moderately high to high sensitivity to IHSF115. It
is noted that the inhibitor was also highly cytotoxic in two
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breast cancer lines (CAMA-1, MDA-MB-231) and an Ew-
ing sarcoma line (A673).
Mode of IHSF115-induced cell death
To ascertain that cancer cells were in fact killed by IHSF115,
parallel sets of HeLa andMM.1S cell cultures were exposed
for 6, 15, 24 or 96 h to increasing concentrations of the com-
pound. Cells were stained with Trypan Blue, and stained
(necrotic) and unstained (live) cells were counted. Figure
7A shows numbers of live cells, and Figure 7B percentages
of dead cells. Exposure to IHSF115 reduced the number of
live cells and increased the number of necrotic cells in both
concentration- and time-dependent fashions. Whereas cell
killing trumped proliferation of MM.1S cells already at a
3.125 M concentration of IHSF115, much higher concen-
trations were needed for HeLa cells. At 12.5 or 25 M con-
centrations of IHSF115, most MM.1S cells were killed after
6 h of exposure. Longer exposures were required to achieve
comparable effects in HeLa cells.
To investigate whether apoptosis was a major mecha-
nism of death after treatment with IHSF115, cells exposed
to the compound for 6 h were double-stained with Annexin
V-FITC and 7-AAD. Live apoptotic cells (Annexin V+/7-
AAD−) are expressed as a percentage of all live cells (7-
AAD−) in Figure 7C. We found that in MM.1S cells the
percentage of live apoptotic cells increased with compound
concentration, surpassing 20% at a 12.5 Mconcentration.
(Essentially no live cells were left after exposure to 25 M
IHSF115.) In HeLa cells, an increase in live apoptotic cells
could only be observed at 25MIHSF115.We conclude that
an apoptotic mechanism of cell death plays a far more im-
portant role in MM.1S cells than in HeLa cells. A cell cy-
cle analysis corroborated the latter conclusion (Figure 7D).
The percentage ofMM.1S cells in sub-G0/G1 fractions rose
to almost 13% (at 12.5Mcompound) after 6 h and to 43%
(at 3.125 Mcompound) after 15 h of exposure to IHSF115.
Thus, a large fraction of MM.1S cells was killed by apopto-
sis induced by IHSF115. In contrast, only about 6% of HeLa
cells exposed to 25 M compound for 24 h were found in
sub-G0/G1 fractions, suggesting that the large majority of
these cells experienced death by a non-apoptotic mecha-
nism.
DISCUSSION
It appears to be a widely held belief that transcription
factors lacking a ligand-binding domain are essentially
‘undruggable’, i.e not specifically targetable by drug-like
molecules (59,60). Nevertheless, there are rare examples
where small-molecule drug candidates were successfully de-
veloped. In these cases, drugs were aimed at interrupting
well-defined protein–protein interactions, e.g. the MDM2–
p53 interaction (61). The approach that we have taken in
this study appears to be unusual, or possibly unique, in
that it did not target any known interaction between a
transcription factor, here HSF1, and a co-factor. Instead,
it consisted of a rational drug development program in-
volving molecular modeling, identification of binding cav-
ities, design of appropriate pharmacophores, assembly of
a small library of lead-like compounds satisfying phar-
macophore criteria and employment of a discriminating
screeningmethod to identify a lead compound that was sub-
sequently improved by standard medicinal chemistry. That
this approach yielded an inhibitor of HSF1 that is effective
at high submicromolar/low micromolar concentrations, i.e.
in a concentration range in which many approved drugs
and drug candidates are active, should be encouraging. Our
findings may catalyze the development of a novel cancer
therapeutic. Concerning the many other not-liganded tran-
scription factors that represent preferred therapeutic tar-
gets, the present study may give an indication that not all
of them may be undruggable.
IHSF115 does not interfere with heat-induced HSF1
oligomerization andHSEDNAbinding. ChIP experiments
showed that IHSF115 also does not reduce HSF1 binding
to intact chromatin. Hence, either nuclear import of HSF1
is not inhibited, or it is not of critical importance. How-
ever, apparent binding of HSF1 to chromatin was reduced
by IHSF058. This observation may be readily explained as
a consequence of HSF1 degradation that this inhibitor
causes. That the inhibitors do not affect HSF1 DNA bind-
ing is consistent with their design. Lead compound 001
from which they were derived was selected based on its ex-
pected ability to bind a pocket in the HSF1 DNA-binding
domain that is not proximal to its DNA interaction region.
We note that minor differences in the structure of the in-
hibitors can result in significantly different effects onHSF1.
IHSF058 but not IHSF115 induces degradation of the tran-
scription factor. Apparently, the two compounds differently
affect HSF1 conformation and/or access of protein cofac-
tors.
Since IHSF115 does not interfere with HSF1 binding to
chromatin, the compound appears to regulate the transcrip-
tional activity of the factor. We found that IHSF115 inhibits
binding of ATF1 to HSF1. Previous work had shown that
ATF1 is a pivotal component of the transcription factor
complexes that mediate HSF1 target gene transcription in
heat-shocked cells (19). Interestingly, ATF1 interacts with a
region within the DNA-binding domain of HSF1. This in-
teraction may be weakened by a conformational change in
the HSF1 DNA-binding domain induced by IHSF115. Al-
ternatively, the inhibitor may interfere directly with ATF1
docking by binding to the same or an adjacent site.
As IHSF115 does not appear to affect heat stress signal-
ing and does not inhibit heat-induced HSF1 DNA binding
but transcription initiation, the inhibitor can be used to ob-
tain a ‘snapshot’ of heat-induced or heat-repressed HSF1-
mediated transcription. The inhibitor probes transcription
when transcription factors including HSF1 are assembled
on the genes and reveals the genes in which HSF1 control
over transcription predominates. This view of the transcrip-
tion process could not be obtained if IHSF115 also inhibited
HSF1 DNA binding. With HSF1 unable to bind, control
over transcription of certain heat-regulated genes may be
usurped by other transcription factors that are capable of
conveying heat regulation (52), but which factors are nor-
mally subrogated to HSF1. An analogous situation may be
created by HSF1 knockdown or genetic deletion.
When we analyzed the effects of heat treatment on
the HeLa cell transcriptome, we observed that the ma-
jority (nearly 2/3) of heat-induced genes were inhibited
by IHSF115, i.e. were positively regulated by HSF1. All
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Figure 7. IHSF115-induced cell death. (A and B) HeLa or MM.1S cells were exposed to the indicated concentrations of IHSF115, or to vehicle (−), for 6,
15, 24 or 96 h. Trypan blue dye exclusion was used to determine numbers of alive cells (A) and percentages of necrotic cells (B). *P < 0.05; comparing to
cells exposed to vehicle at each time point. (C) HeLa and MM.1S cells were exposed to the indicated concentrations of IHSF115, or to vehicle (−), for 6 h
and then double-stained with Annexin V-FITC and 7-AAD. Percentages of early apoptotic cells (Annexin V+/7-AAD-) are shown. *P< 0.05; comparing
to the corresponding cell type exposed to vehicle. (D) DNA contents of HeLa or MM.1S cells that had been exposed to the indicated concentrations of
IHSF115, or to vehicle (−), for 6, 15 and 24 h. Percentages of apoptotic cells are indicated within the histograms.
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genes for which a statistically significant effect of the in-
hibitor could not be obtained were counted as not regu-
lated by HSF1 (‘not-inhibited’). We noticed that the fre-
quency of HSF1-inhibited versus not-inhibited genes de-
creased with decreasing heat inducibility, whereas the effec-
tiveness of inhibition by IHSF115 increased. We take this to
reflect a limitation of the analysis. Small inhibitory effects
can be expected to be increasingly unlikely to reach statis-
tical significance as the differential between heat-induced
and basal expression level decreases. Taking this into ac-
count, our extrapolation suggests that most heat-induced
genes may be regulated byHSF1. Hence, our study suggests
that HSF1 plays a predominant role in the transcription of
heat-induced genes. Earlier studies had reached the oppo-
site conclusion, i.e. that the large majority of heat-induced
genes are not regulated by HSF1 (29,52). In the latter stud-
ies, absence of heat induction in cells in which HSF1 was
knocked out or knocked down, respectively, was used as
the criterion for deciding whether a heat-induced gene is
HSF1-regulated. As discussed above, a reason for the dif-
ference in the number of genes considered HSF1-regulated
between an HSF1 inhibitor-based study and a compara-
tive analysis of HSF1-containing and HSF1-deficient cells
may be that ‘secondary’ heat regulation of certain genes
may take over in HSF1-deficient cells with the result that
HSF1-regulated genes are missed. Establishment of such
secondary regulation may be facilitated by various tran-
scriptomic and/ormetabolic adaptations thatHSF1 knock-
down or knockout cells may have undergone to compensate
for the HSF1 deficiency. Consistent with this hypothesis is
that many positively HSF1-regulated genes contain bind-
ing sites for transcription factors suggested to be capable of
conferring heat regulation such SRF (about 60% of genes),
and E2F2 (about 33% of genes), NFE2L2 (about 13% of
genes), YY2 (about 57% of genes) and ELF1(about 60% of
genes).
All studies agree that most of the heat-repressed genes are
repressed by a mechanism that does not involve HSF1. For
the minority of genes that are HSF1-regulated, repression
was proposed to be brought about byHSF1molecules bind-
ing to intragenic sites and obstructing progression of RNA
polymerase (62,63). Recent evidence argues against such a
mechanism: no accumulation of RNA polymerase could be
detected upstream from intragenic HSF1 binding sites (52).
Our finding that IHSF115 prevents or attenuates the heat-
induced repression of certain genes even though the com-
pound does not interfere with HSF1 DNA binding is in
keepingwith the latter evidence. It would also appear to rule
out the possibility that repression can be caused by HSF1
molecules binding to promoter regions and interfering with
transcription initiation. Instead, it suggests that repression
is mediated by transcriptionally active HSF1 molecules.
A consensus HSE sequence was defined for a subgroup
of the positively HSF1-regulated genes identified in this
study. Somewhat surprisingly, this consensus sequence was
markedly degenerate when compared to a consensus se-
quence derived from a group of classicalHSP genes or from
HSF1-binding sites defined by ChIP-Seq (30). Thus, certain
genes are heat-regulated by HSF1 despite containing only
rudimentary HSEs. Stable binding of HSF1 to chromatin
appears to require better defined HSEs. Barring technical
explanations, these observations support a view that HSF1
is capable of directing transcription through subtle interac-
tions with promoter DNA, which interactions may be sta-
bilized and/or enhanced by other transcription factors and
co-factors.
Cancer cells frequently exhibit a dependency on HSF1
activity for survival and proliferation as was first demon-
strated in the pioneering study of Dai et al. (31). In the same
study, the cytotoxic effect of HSF1 depletion by siRNAwas
examined in a panel of human cancer cell lines, of which
some were also present in the panel tested in the present
study (Figure 6B). Sensitivity to HSF1 depletion (by hA6
shRNA) decreased in the following order: HeLa > T47D
> MDA-MB-231 > MCF-7 > PC-3/BT-20 > BT-474. In
the present study, the order was MDA-MB-231 > PC-3 >
T47D > MCF-7/BT-474 > HeLa > BT-20 (Figure 6B).
Based on this limited sample of cell lines, it would appear
that cancer cell lines respond differently to HSF1 depletion
and HSF1 inhibition. For example, HeLa cells are highly
sensitive to HSF1 depletion but not to HSF1 inhibition.
While there may be multiple possible reasons for these dif-
ferences in responsiveness, one that is difficult not to con-
sider is that inhibition involves an acute drop in HSF1 ac-
tivity while depletion is a process that occurs over many
hours/days. The slow process of HSF1 depletion may al-
low for transcriptomic and/or metabolic changes in cancer
cells that mitigate or enhance the cytotoxic effect of loss of
HSF1 activity, which changes may not occur upon abrupt
disruption of HSF1 function.
After the work reported herein had been completed,
structural information on human HSF1 and HSF2 became
available (PDB entries and refs. 64,65). HSF1 crystal struc-
tures 5D5U, 5D5V and the NMR structure of 2LDU show
a cavity in a similar position to that of cavity A in our ho-
mology model. Admittedly, the cavities in 5D5U and 5D5V
have a slightly different shape to our homology model, and
it may be difficult for the docking program to give a po-
tential pose for the hit molecules against these new crystal
structures. However, the 2LDU NMR structure has 20 dif-
ferent conformations that adhere to the NMR data, show-
ing the residues which line the pocket can be modeled in
different positions. Given that a number of protein confor-
mations can be generated that satisfy the NMRdata, we be-
lieve that more conformations are potentially available and
that (our model of) cavity A represents a feasible confor-
mation that can be considered. There may also be an el-
ement of ‘induced fit’ where the protein could respond to
the presence of an IHSF. From the 5D5U and 5D5V crystal
structures, we believe that cavity A is accessible when HSF1
is complexed with DNA. It is noted that the pocket is also
present in theHSF2 crystal structures 5D8K and 5D8L, but
again its shape is slightly different when compared with the
HSF1 crystal structures, although this pocket may be able
to change dynamically. Consequently, it is not inconceivable
that IHSF could also target HSF2.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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